European Journal of Pharmaceutics and Biopharmaceutics最新文献

{"title":"Electrospun-lyophilized chitosan wound dressings for dual bioactive delivery of hyaluronic acid and IL-6.","authors":"Annika Horchler, Marie-Christine Rau, Viktoria Planz, Maike Windbergs","doi":"10.1016/j.ejpb.2026.115263","DOIUrl":"https://doi.org/10.1016/j.ejpb.2026.115263","url":null,"abstract":"<p><p>Wound healing is a complex and highly regulated cellular process with limited therapeutic interventions despite its substantial clinical burden. Current research shifts towards endogenous biomolecules as promising wound healing candidates, including hyaluronic acid and interleukin-6. However, despite their clinical potential such molecules pose significant technological challenges due to their fragility, limiting their clinical application. To overcome these limitations, a bilayer wound dressing was developed combining electrospinning and freeze drying. A chitosan nanofiber mat serves as a physical barrier, while hyaluronic acid and interleukin-6 were transformed into a hydrophilic wound-healing-promoting layer via freeze drying, enabling immediate and wound-phase-specific delivery of interleukin-6. Hyaluronic acid acts as a stabilizer for interleukin-6, enhancing its recovery by about 30 % and initial storage stability. The wound dressing demonstrates high biocompatibility, with a cell viability of 126 % and reduces the residual wound area and accelerates wound closure by more than 40 % after 48 h compared to the control. Further, pronounced antibacterial activity of chitosan is proven against S. aureus and P. aeruginosa, further enhanced by hyaluronic acid through increased protonation of amino groups. These results provide proof-of-concept for the potential of this bilayer system as a multifunctional platform for the stable and effective delivery of fragile biomolecules enabling modern wound therapy.</p>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":" ","pages":"115263"},"PeriodicalIF":5.0,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure-interaction-performance relationships in quercetin-based co-amorphous systems: insights from molecular simulations and experimental characterization.","authors":"Iqra Aslam, Abinash Nayak, Mohd Fakharul Zaman Raja Yahya, Isra Khatib, Niall J O'Reilly, Nasser Alhajj","doi":"10.1016/j.ejpb.2026.115262","DOIUrl":"https://doi.org/10.1016/j.ejpb.2026.115262","url":null,"abstract":"<p><p>Quercetin (QUE) has recently attracted increasing interest as a co-former in co-amorphous systems owing to its multiple hydrogen-bonding functionalities. However, the relationship between its intermolecular interactions and co-amorphous performance remains poorly understood. This study investigated the influence of co-former chemistry on the molecular interactions, stability, and aqueous performance of quercetin-based co-amorphous systems using arginine (ARG) and glutamic acid (GLU) as model amino acid co-formers. Co-amorphous formulations were prepared by spray drying and characterized using molecular modelling, solution-state ¹H NMR titration, FTIR spectroscopy, PXRD, mDSC, dynamic vapour sorption, solubility, and dissolution studies. Molecular simulations predicted stronger miscibility and intermolecular interactions in the QUE-ARG systems than in the corresponding QUE-GLU systems, which was supported by NMR and FTIR analyses. Although all formulations were initially amorphous, the QUE-GLU systems crystallized within one week of storage, whereas the QUE-ARG systems remained amorphous for at least three months. Notably, the QUE-GLU formulations exhibited comparable or higher glass-transition temperatures, indicating that Tg alone was not predictive of physical stability. The stronger interactions observed in the QUE-ARG systems were also associated with substantially improved saturated solubility and dissolution performance. These findings demonstrate that the effectiveness of quercetin as a co-former depends on the nature and specificity of intermolecular interactions and highlight their importance in the rational design of quercetin-based co-amorphous systems.</p>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":" ","pages":"115262"},"PeriodicalIF":5.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Localized nano-doxycycline platforms for antimicrobial and regenerative oral therapy: A systematic review.","authors":"Bakr Ahmed, Hadeel Adel Al-Lami, Pornanong Aramwit, Syed Mahmood","doi":"10.1016/j.ejpb.2026.115239","DOIUrl":"https://doi.org/10.1016/j.ejpb.2026.115239","url":null,"abstract":"<p><strong>Background: </strong>Local doxycycline is used in periodontal therapy for antimicrobial and host-modulatory purposes, but conventional systemic and local formulations have limitations related to exposure, retention, release control and application-specific functionality. Nano-enabled systems have been investigated across periodontal, regenerative, implant, endodontic, dentinal, pulpal and oral-mucosal applications.</p><p><strong>Methods: </strong>PubMed/MEDLINE, Scopus and ScienceDirect were searched for original studies published from 2010 to July 2025. Study eligibility, evidence level, formulation characteristics, dose, drug loading, release, biological outcomes and risk of bias were assessed. Randomized human studies were evaluated using RoB 2, the non-randomized human study using ROBINS-I, animal studies using SYRCLE and laboratory studies using QUIN. Patent records were appraised separately and were not treated as therapeutic evidence.</p><p><strong>Results: </strong>Eligibility reappraisal retained 21 studies: five human, four animal and 12 in-vitro or ex-vivo investigations. Human evidence was limited mainly to adjunctive periodontal-pocket therapy, whereas implant, regenerative, endodontic, dentinal and pulpal applications remained predominantly preclinical. Reported systems included nanogels, PLGA nanospheres, electrospun fibres and membranes, polymersomes, liposomes, nanotubes, implant coatings and mineral carriers. Dimensional characterization was common, but administered dose, measured loading, encapsulation efficiency and standardized release data were inconsistently reported. Formal local or systemic pharmacokinetic parameters were generally absent. Methodological concerns included small samples, incomplete randomization or blinding, limited dose-matched comparators and heterogeneous outcome definitions. Patent reassessment identified an adjacent and partly out-of-scope landscape rather than evidence of commercial readiness.</p><p><strong>Conclusions: </strong>Localized nano-doxycycline demonstrates formulation feasibility and application-specific biological or early clinical signals, but the evidence does not establish class-wide superiority over conventional doxycycline. Future studies require standardized formulation reporting, local and systemic exposure measurements, dose-matched controls, resistance surveillance, long-term safety, scalable manufacturing and adequately powered clinical trials.</p>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":" ","pages":"115239"},"PeriodicalIF":5.0,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-birds-one-stone, microfluidic producing DES/W microemulsions to solubilize quercetin and penetrate intestinal mucosa for enhanced oral bioavailability","authors":"Ruirui Liu,&nbsp;Xiu Yang,&nbsp;Chaoqi Huang,&nbsp;Xiaoduo Guan,&nbsp;Yixin Li,&nbsp;Gensheng Yang,&nbsp;Qingliang Yang","doi":"10.1016/j.ejpb.2026.115007","DOIUrl":"10.1016/j.ejpb.2026.115007","url":null,"abstract":"<div><div>Quercetin has antioxidant, anti-inflammatory, antibacterial, and anticancer effects. However, its therapeutic efficacy is limited by poor water solubility, low oral absorption, and limited bioavailability. In this study, a novel deep eutectic solvent (DES) in water (DES/W) microemulsion system was developed, wherein the DES was composed of DL-menthol and capric acid at a molar ratio of 7:3, to simultaneously accomplish enhanced quercetin solubilization and promoted mucosal permeation, both of which ensuring an adequate oral bioavailability and sufficient therapeutic effectiveness. Optimized DESs were used with microfluidic technology to create uniform quercetin-loaded DES/W microemulsions under the optimal formulation conditions: Tween 20 as the surfactant, a surfactant concentration of 1.37%, a continuous phase flow rate of 30.98 mL/h, and a dispersed phase flow rate of 3.15 mL/h. The results showed that the obtained microemulsions increased quercetin solubility, retention time in the intestines, and mucosal absorption, improving drug absorption and bioavailability. Pharmacokinetic studies showed that compared with free quercetin, the area under the plasma concentration–time curve (AUC_0～t) and maximum plasma concentration (C_max) of the microemulsion formulation were significantly increased, with AUC_0～t being 5.54-fold higher than that of free quercetin. Notably, the use of microfluidic technology in preparing these microemulsions considerably reduces the need for surfactants, thus enhancing the biosafety of DES-based microemulsions. Overall, the DES/W microemulsions prepared by microfluidics could effectively addresses the challenges associated with poor absorption and low bioavailability of insoluble drugs with highly monodisperse and uniform formulations.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"222 ","pages":"Article 115007"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Site-specific targeting in immunoliposomal nanomedicine for oncology: opportunities and limitations","authors":"Małgorzata Milczarek ,&nbsp;Patrycja Kleczkowska (-)","doi":"10.1016/j.ejpb.2026.115004","DOIUrl":"10.1016/j.ejpb.2026.115004","url":null,"abstract":"<div><div>The integration of monoclonal antibodies with liposomal nanocarriers has opened new possibilities in targeted cancer therapy. Immunoliposomes, which are liposomes surface-conjugated with antibodies or antibody fragments, offer dual specificity by combining passive targeting (via the enhanced permeability and retention effect) with active targeting of tumor-specific antigens. This design allows for increased drug accumulation in tumor tissue and reduced off-target toxicity, which are critical challenges in conventional chemotherapy.</div><div>Although no immunoliposomal therapy has yet received the FDA or EMA approval, the platform continues to evolve. Several formulations are under clinical investigation for various solid tumors, including triple-negative breast cancer, glioblastoma, and non-small cell lung cancer. For example, in a phase II study of anti-EGFR immunoliposomes loaded with doxorubicin in advanced triple-negative breast cancer (NCT02833766), the median progression-free survival was 3.5 months, with 73% of patients experiencing disease progression within the first year.</div><div>Immunoliposomes hold promise as future therapeutic agents, especially when integrated with molecular diagnostics and patient-specific targeting strategies. However, their clinical translation requires overcoming biological and technological barriers to ensure reproducible efficacy and safety. This review critically examines current progress and explores future perspectives for this emerging therapeutic strategy in precision oncology.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"222 ","pages":"Article 115004"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A way forward for generic development of telmisartan tablets: Integrating critical material attributes and bio-predictive dissolution for target product profile","authors":"Megha Pillai,&nbsp;Ravi P. Shah,&nbsp;Pinaki Sengupta","doi":"10.1016/j.ejpb.2026.115010","DOIUrl":"10.1016/j.ejpb.2026.115010","url":null,"abstract":"<div><div>This study systematically integrated critical material attributes (CMAs) influencing drug release, focusing on factors such as particle size and excipient composition, and characterization of polymorphic form. As a model compound, a BCS class II drug Telmisartan was selected, and the methodology was evaluated using seven different formulations of Telmisartan through comprehensive analysis. The orthogonal analytical techniques, including chromatography, hot-stage microscopy, NMR spectroscopy, and dissolution testing were employed for evaluating critical quality attributes (CQAs). Systematic efforts were made to develop a biopredictive dissolution method using USP dissolution Apparatus I, II, and IV. Based on the t_max value of telmisartan, a multi-stage dissolution strategy was developed to understand the behaviour of formulation in acidic and neutral pH corresponding to the stomach and duodenum under fasting conditions. After de-formulation experiments, formulations were categorized into different buckets based on the size of API particles(d90 value of 8 ± 2 µm; 12 ± 2 µm and &gt;15 µm), the type of excipients present (functional excipient and non-functional excipients), and the micro-environmental pH of the formulations. A rank-based approach was applied to evaluate a robust framework for understanding the differences between these generic formulations. This approach not only supports comprehensive formulation development through CMA–CQA correlations, but also aligns with regulatory expectations for adopting multi-dissolution methods as <em>in vitro</em> testing in cases of formulation change requirements with a bioequivalence waiver for post-approval formulation changes.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"222 ","pages":"Article 115010"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in metal–organic framework-based drug delivery system in cuproptosis-mediated cancer therapy","authors":"Haodong Ruan ,&nbsp;Yenuo Chen ,&nbsp;Junlin Qian ,&nbsp;Xiaomu Ma ,&nbsp;Yinna Xu ,&nbsp;Yijun Deng ,&nbsp;Ying Pan ,&nbsp;Aparna Kushwaha ,&nbsp;Abhinav Kumar ,&nbsp;Biao Zheng ,&nbsp;Jianqiang Liu","doi":"10.1016/j.ejpb.2026.115021","DOIUrl":"10.1016/j.ejpb.2026.115021","url":null,"abstract":"<div><div>Cancer continues to pose an immense burden on global health, ranking among the foremost causes of disease-associated mortality. Conventional diagnostic platforms for tumor biomarkers, while widely adopted, remain constrained by limited sensitivity, protracted workflows, and substantial economic costs, thereby restricting their clinical applicability. Therapeutic modalities such as chemotherapy and radiotherapy further compound the challenge, offering only modest selectivity and being accompanied by significant systemic toxicity and a high likelihood of relapse. Metal-organic frameworks (MOFs) represent a class of structurally tailorable nanomaterials composed of modular building units, featuring tunable porosity and favourable biocompatibility, which together provide an efficient platform for drug encapsulation and controlled release. Their tumour accumulation behaviour is strongly governed by key physicochemical parameters, including particle size, morphology, and surface chemistry. Pristine MOFs primarily rely on passive tumour targeting through the enhanced permeability and retention effect, whereas surface functionalization with targeting ligands can markedly improve tumor selective enrichment and cellular uptake. Consequently, the therapeutic delivery performance of MOFs must be critically assessed in relation to their specific structural design and surface engineering strategies. In parallel, the identification of cuproptosis, a mitochondria-centered copper-dependent mode of regulated cell death, has opened a distinct mechanistic avenue for oncological intervention. This process arises from the aberrant interaction of copper ions with lipoylated tricarboxylic acid cycle proteins, culminating in excessive protein acylation, destabilization of Fe–S cluster enzymes, proteotoxic stress, and mitochondrial collapse. The rapid evolution of pharmacological agents exploiting this pathway underscores its transformative therapeutic potential. This review critically consolidates recent progress at the interface of MOFs and cuproptosis, emphasizing design strategies, mechanistic insights, and therapeutic deployment, while also addressing unresolved issues in pharmacokinetics, biosafety, and translational feasibility that must be overcome for clinical realization.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"222 ","pages":"Article 115021"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146186428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of anti-EGFR targeted magnetic nanoparticles for doxorubicin delivery into triple negative breast cancer cells","authors":"Chloé Lameli ,&nbsp;Stéphanie David ,&nbsp;Emilie Allard-Vannier ,&nbsp;Gaëlle Dupeyrol ,&nbsp;Fanny Boursin ,&nbsp;Nicolas Aubrey ,&nbsp;Igor Chourpa ,&nbsp;Katel Hervé-Aubert","doi":"10.1016/j.ejpb.2026.115009","DOIUrl":"10.1016/j.ejpb.2026.115009","url":null,"abstract":"<div><div>A new generation of pH-responsive magnetic theranostic nanovectors (NV) has been developed to deliver doxorubicin (DOX) to triple negative breast cancer (TNBC) cells which overexpress epidermal growth factor receptor (EGFR). DOX was loaded onto functionalized NV using a pH-sensitive DOX-Fe²⁺ complex (hereafter called NV_scFv-DOX). NV_scFv-DOX consist of superparamagnetic iron oxide nanoparticles (SPIONs), labelled with Dylight^TM 680 fluorophore, and coated with a layer of covalently bound polyethylene-glycol (PEG) which is partially functionalized with anti-EGFR scFvs (average ratio is ≈12 scFvs per nanovector). The physico-chemical characteristics of the new nanovectors were suitable for IV injection: hydrodynamic diameter D_H below 150 nm, polydispersity index below 0.3 and slightly negative surface charge (≈ −10 mV). Thanks to the functional grafted scFvs, the NV_scFv-DOX were able to recognize the EGFR antigen efficiently. Using preformed DOX-Fe²⁺ complex which binds to the SPION surface in a pH-dependent manner, about 6.5% w/w (DOX/iron oxide) of the drug was loaded onto the NV_scFv-DOX. The drug loading and release in its native form at acidic pH were characterized by surface-enhanced Raman scattering (SERS) spectroscopy. The dual fluorescent response of both Dylight^TM680 and that of DOX was confirmed, which is promising for theranostic use of the nanovectors. Finally, the <em>in vitro</em> toxicity of NV_scFv-DOX on the EGFR-overexpressing TNBC cell line MDA-MB-468 was confirmed and compared to that of free DOX and NV_scFv without DOX. Together, all these properties of the NV_scFv-DOX are promising for their potential use as theranostic platform for TNBC treatment.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"222 ","pages":"Article 115009"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strain- and species-specific immune responses to human adipose stem cell-derived extracellular vesicles: A comparative pharmacological evaluation in mice and human PBMCs","authors":"Dong Oh Kim ,&nbsp;Quy Thi Nguyen ,&nbsp;Young Chan Choi ,&nbsp;Ji Suk Choi ,&nbsp;Kyoung Soo Lee ,&nbsp;Yong Woo Cho ,&nbsp;Min Heui Yoo","doi":"10.1016/j.ejpb.2026.115008","DOIUrl":"10.1016/j.ejpb.2026.115008","url":null,"abstract":"<div><div>Human adipose stem cell-derived extracellular vesicles (hASC-EVs) have gained attention as potential cell-free therapeutics in regenerative medicine due to their immunomodulatory properties and low immunogenicity. Despite this promise, their immunotoxicity profile remains insufficiently characterized, particularly across species and genetic backgrounds. This study systematically assessed immune responses to repeated high-dose intravenous administration of hASC-EVs in two murine strains—C57BL/6 (inbred) and ICR (outbred)—and in human peripheral blood mononuclear cells (hPBMCs) in vitro. Flow cytometry of murine blood and spleen samples revealed transient, strain-dependent shifts in immune cell populations, including neutrophils, monocytes, macrophages, B cells, and NK cells. Notably, C57BL/6 mice exhibited more pronounced fluctuations than ICR mice, reflecting the role of host genetics in EV-induced immunomodulation. In contrast, hPBMCs exposed to equivalent concentrations of hASC-EVs displayed no significant changes in cell viability, immune cell subset composition, or activation markers over a 24-hour period. While a mild, transient increase in CD86⁺ monocytes was observed at 6 h, this effect normalized by 12 h. These results suggest that hASC-EVs induce minimal and reversible immune responses in vivo and are immunologically inert in human immune cells under the tested conditions. The strain- and species-specific differences observed emphasize the limitations of rodent-only models for predicting human immunotoxicity and support the incorporation of human immune cell assays into preclinical safety assessments of EV-based therapeutics.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"222 ","pages":"Article 115008"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146098600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fabrication of bioprints self-coated with thermally sensitive lactobacilli for CAUTI applications","authors":"Caden Maners ,&nbsp;Anthony J. Kyser ,&nbsp;Davis Verhoeven ,&nbsp;Bassam Fotouh ,&nbsp;Arielle Greiner ,&nbsp;Nicole M. Gilbert ,&nbsp;Hermann B. Frieboes","doi":"10.1016/j.ejpb.2026.114993","DOIUrl":"10.1016/j.ejpb.2026.114993","url":null,"abstract":"<div><div>Catheter-associated urinary tract infections (CAUTI) represent a large healthcare burden, accounting for a substantial portion of hospital-acquired infections in the United States. Solutions such as intermittent catheterization and catheter surface coatings with antibiotics or silver nanoparticles have offered limited success in preventing uropathogen biofilm formation on the catheter or in promoting a healthy urinary tract. This study explores a novel self-coating biomaterial approach for CAUTI applications, with the goal to promote antibacterial interference. A new fabrication technique is developed to incorporate thermally sensitive <em>Lactobacillus</em> bacteria into a silicone-based polymer. These species are known for their probiotic capabilities and were selected as a means for the material to self-coat with them. Using 3D-printed CAD-designed molds and bio-injection molding, “living probiotic carrier” catheter segments were formed with the probiotic-containing bioink. <em>Lactobacillus</em>-containing segments immersed in artificial urine media (AUM) increased in mass up to 7 days and remained stable at physiological conditions. Increased absorbance via crystal-violet staining indicated biomass accumulation while SEM imaging revealed a visibly large probiotic presence on the segment intraluminal surface over 7-day submersion in AUM. Mechanical integrity testing yielded Shore A hardness values within clinically acceptable ranges. TGA and DSC thermal stability analyses suggested that probiotic presence could affect silicone crosslinking, highlighting the need to fine-tune loading amount and composition of bacterial species to achieve desired polymeric degradation. Overall, the results demonstrate promising biomaterial properties along with lactobacilli biofilm formation, highlighting the potential for silicone catheters self-coated by thermally sensitive lactobacilli to offer a bacterial interference strategy against CAUTI.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"221 ","pages":"Article 114993"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}